Natali Jokanovic

Natali Jokanovic

Auto-generated profile, based on publicly available information

Natali Jokanovic

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
NJNatali Jokanovic
Natali Jokanovic
ETEdwin Tan
Edwin Tan
MDMichael J. Dooley
Michael J. Dooley
CKCarl Michael James Kirkpatrick
Carl Michael James Kirkpatrick
JBJ. Simon Bell
J. Simon Bell

1 July 2017 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
NJNatali Jokanovic
Natali Jokanovic
ETEdwin Tan
Edwin Tan
SSSreeja Sudhakaran
Sreeja Sudhakaran
CKCarl Michael James Kirkpatrick
Carl Michael James Kirkpatrick
MDMichael J. Dooley
Michael J. Dooley
JBJ Simon Bell
J Simon Bell

19 December 2016 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
BWBarbara C Wimmer
Barbara C Wimmer
ACAmanda J Cross
Amanda J Cross
NJNatali Jokanovic
Natali Jokanovic
MWMichael D Wiese
Michael D Wiese
JGJohnson George
Johnson George
JBJ. Simon Bell
J. Simon Bell

1 May 2016 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
NJNatali Jokanovic
Natali Jokanovic
ETEdwin Tan
Edwin Tan
DBDenise van Den Bosch
Denise van Den Bosch
CKCarl Michael James Kirkpatrick
Carl Michael James Kirkpatrick
MDMichael J. Dooley
Michael J. Dooley
JBJ Simon Bell
J Simon Bell

20 August 2015 in Current Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JIJenni Ilomaki
Jenni Ilomaki
NJNatali Jokanovic
Natali Jokanovic
ETEdwin Tan
Edwin Tan
ELEija Lonnroos
Eija Lonnroos
There is uncertainty in relation to the effect of alcohol consumption on the incidence of dementia and cognitive decline. This review critically evaluated published systematic reviews on the epidemiology of alcohol consumption and the risk of dementia or cognitive decline. MEDLINE, EMBASE and PsycINFO were searched from inception to February 2014. Systematic reviews of longitudinal observational studies were considered. Two reviewers independently completed the 11-item Assessment of Multiple Systematic Reviews (AMSTAR) tool to assess the quality. We identified three moderate quality systematic reviews (AMSTAR score 4-6) that included a total of 45 unique studies. Two of the systematic reviews encompassed a meta-analysis. Light to moderate drinking may decrease the risk of Alzheimer’s disease (AD) (pooled risk ratio [RR] 0.72; 95% confidence interval [CI] 0.61-0.86) and dementia (RR 0.74; 95%CI 0.61-0.91) whereas heavy to excessive drinking does not affect the risk (RR 0.92; 95%CI 0.59-1.45 and RR 1.04; 95%CI 0.69-1.56, respectively). One systematic review identified two studies that reported a link between alcohol consumption and the development of AD. No systematic review categorised former drinkers separately from lifetime abstainers in their analysis. Definitions of alcohol consumption, light to moderate drinking and heavy-excessive drinking varied and drinking patterns were not considered. Moderate quality (AMSTAR score 4-6) systematic reviews indicate that light to moderate alcohol consumption may protect against AD and dementia. However, the importance of drinking patterns and specific beverages remain unknown. There is insufficient evidence to suggest abstainers should initiate alcohol consumption to protect against dementia.

20 August 2015 in Current Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ETEdwin Tan
Edwin Tan
NJNatali Jokanovic
Natali Jokanovic
MKMarjaana P.H. Koponen
Marjaana P.H. Koponen
DTDennis Thomas
Dennis Thomas
SHSarah N. Hilmer
Sarah N. Hilmer
JBJ. Simon Bell
J. Simon Bell
Pain is a frequent cause of discomfort and distress in residents in residential aged care facilities (RACFs). Despite the benefits of adequate pain management, there is inconsistency in the literature regarding analgesic use and pain in residents with dementia. The aim of this systematic review was to determine the prevalence of analgesic drug use among residents with and without dementia or cognitive impairment in RACFs. A systematic search of MEDLINE and EMBASE (inception to January 2014) was conducted using Medical Subject Headings and Emtree terms, respectively. Studies were included if they reported prevalence of analgesic use for residents both with and without dementia within the same study. Data extraction and quality assessment was performed independently by two investigators. Data on the prevalence of analgesic use, pain and painful conditions were extracted. Meta-analyses were performed using random effect models. The 7 included studies were of high quality (≥5 out of 7 on the adapted Newcastle-Ottawa Scale). Analgesic use in residents with and without dementia or cognitive impairment ranged from 20.2% to 61.2% and 38.8% to 79.6%, respectively. Paracetamol was the most prevalent analgesic in people with and without dementia. Residents with dementia or cognitive impairment had a significantly lower prevalence of analgesic use (odds ratio [OR] 0.576, 95% confidence interval [CI] = 0.406-0.816) and of self-reported and clinician-observed pain (OR 0.355, 95% CI = 0.278-0.454) than residents without cognitive impairment, despite a comparable prevalence of painful conditions. These findings may indicate under-reporting and under-detection of pain in persons with dementia, and subsequent suboptimal treatment.